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Background: There is wide variability in reported venous thromboembolism (VTE) incidence 
following total shoulder replacement (TSR) or total elbow replacement (TER). It is uncertain which 
risk factors influence the risk of VTE following TSR or TER. We conducted a PRISMA compliant 
meta-analysis to evaluate the incidence, temporal trends and potential risk factors for VTE following 
primary TSR and TER. 
Methods: MEDLINE, Embase, Web of Science, and Cochrane Library were searched through 
September 2019 for longitudinal studies reporting VTE outcomes after TSR or TER. Incidence and 
relative risks (RR) (95% confidence intervals) were estimated.  
Results: We identified 43 articles with data on 672,495 TSRs and TERs (668,699 TSRs and 3,796 
TERs). The overall pooled 3-month VTE incidence following TSR was 0.85% (0.39-1.46). For TER, 
the 3-month incidence of VTE was 0.23% (0.08-0.44). Older age, body mass index (BMI) ≥25 kg/m2, 
and alcohol abuse were each associated with increased VTE risk following TSR. Comorbidities 
associated with increased VTE risk following TSR were chronic pulmonary disease, previous VTE, 
heart failure, anaemia, coagulopathy, arrhythmia, epilepsy, urinary tract infection, sleep apnoea, and 
fluid & electrolyte imbalance. Anatomic and outpatient TSR were each associated with decreased 
VTE risk. 
Conclusions: The average 3-month incidence of VTE following TSR or TER is less than 1%. High 
risk groups such as older patients, those with a previous VTE history and those undergoing reverse or 
inpatient TSR may need close monitoring. Modifiable factors such as high BMI, alcohol abuse, and 
comorbidities could be identified and addressed prior to surgery. 
 
Systematic review registration: PROSPERO 2019: CRD42019134096 
Keywords: incidence; risk factor; venous thromboembolism; deep vein thrombosis; pulmonary 







Venous thromboembolism (VTE), which comprises pulmonary embolism (PE) and deep vein 
thrombosis (DVT), is a frequent complication of total joint replacement (TJR).[1]  VTE carries a 
substantial public health burden, being an important cause of morbidity, high costs to healthcare 
systems and a preventable cause of death.[2] VTE has long been established as a major complication 
of lower extremity joint replacements (i.e., hip and knee) and there is a minefield of literature on the 
its incidence, risk factors, diagnosis, prevention, and treatment. In the absence of pharmacological 
thromboprophylaxis, VTE incidence has been reported to be as high as 40-85% following lower limb 
joint replacement;[1, 2] with routine anticoagulant therapy, VTE rates of 1-10% have been 
reported.[1, 2] Compared to lower extremity joint replacements, relatively few upper extremity 
replacements (total shoulder and elbow replacement, TSR and TER) are performed. In 2018, as 
recorded in the National Joint Registry for England, Wales and Northern Ireland and the Isle of Man, 
99,093 and 92,874 primary joint replacements were performed in knees and hips respectively; 
whereas only approximately 7,000 shoulder and 600 elbow replacements were performed.[3] Given 
the few numbers of TSRs and TERs done every year, the literature is very sparse on the incidence of 
VTE and potential risk factors that influence VTE incidence. Whereas there are established guidelines 
on the use of thromboprophylaxis in patients undergoing hip and knee replacements, those for 
shoulder and elbow replacements are not clearly defined.[4] VTE has typically been considered an 
uncommon complication after shoulder or elbow replacement. However, limited published literature 
suggest that VTE incidence following shoulder and elbow replacements range widely from 0.1% to 
13%.[5-7]  
 
Total joint replacement has gained acceptance as one of the most successful orthopaedic procedures 
for end stage joint disease. Amongst all orthopaedic joint replacements, shoulder replacements are the 
most rapidly growing and it is expected there will be a seven-fold increase over the next 15 years.[8] 
Hence, there is a need for robust data on the actual incidence of VTE and identification of patients 
who are at the greatest risk of developing VTE following TSR or TER. This information will be of 
value for policy makers and clinicians to aid in planning and implementing more efficacious 
 
 
preventative strategies. Furthermore, though there is established evidence that several host-related 
factors are associated with the risk of VTE following total hip and knee replacement,[9] it is uncertain 
if these potential risk factors also influence VTE risk following TSR or TER in a similar way. In this 
context, using a systematic meta-analytic approach, we sought to (i) assess and pool incidence of VTE 
(including DVT and PE) following primary TSR and TER and characterise their temporal trends; and 
(ii) quantify the nature, magnitude and specificity of potential associations of several patient-, 




Methods and methods 
2.1. Data sources and search strategy 
This review was based on a pre-defined protocol which was registered with the prospective register of 
systematic reviews, PROSPERO (CRD42019134096) and was conducted using PRISMA and 
MOOSE guidelines (Appendices A-B). We performed an electronic search of MEDLINE, Embase, 
Web of Science and Cochrane databases from inception to 26 September 2019 for studies reporting on 
VTE outcomes (DVT and/or PE) following TSR or TER.  The computer-based searches combined 
free and MeSH search terms and combination of key words related to the population (e.g., “total 
shoulder replacement”, “total elbow replacement”) and outcome (e.g., “venous thromboembolism”, 
“deep vein thrombosis”, “pulmonary embolism”). There were no restrictions on language. Full details 
of the search strategy are reported in Appendix C. The titles and abstracts of retrieved studies were 
initially screened to assess their suitability for inclusion, after which we acquired full texts of 
potentially relevant articles for detailed evaluation. Two reviewers independently conducted full text 
evaluation and any disagreements regarding eligibility of an article was discussed, and consensus 
reached with a third author. Reference lists of identified studies and relevant review articles were 
scanned manually and the “Cited Reference Search” function in Web of Science was used to check 
for additional eligible studies. 
 
2.2. Eligibility criteria 
Longitudinal studies (prospective or retrospective cohort, case-cohort, nested-case control, or clinical 
trials) were eligible for inclusion if they recruited patients who had undergone primary TSR (anatomic 
(ATSR) or reverse (RTSR)) or TER, reported on cases of VTE (DVT and/or PE) following the 
surgery and/or reported on the associations of VTE with patient-related factors (such as 
sociodemographic characteristics, anthropometric measures, or past medical and/or surgical history), 
surgery-related factors (such as surgical approach, procedure type, or use of bone cement), or 
hospital-related factors (such as hospital volume or surgeon experience). The primary outcome was 
VTE, including either DVT or PE. We excluded the following studies: (i) those restricted to patients 
with prevalent disease conditions (e.g. diabetes, epilepsy etc) or selected populations with no 
 
 
comparison or control groups; (ii) those that assessed exposures (potential risk factors) after the joint 
replacement; and (iii) of any other surgical approach apart from total elbow or shoulder replacement 
such as in the setting of only infection, fracture, arthroscopy or hemiarthroplasty. Our population 
setting included mainly patients undergoing elective joint replacement, hence joint replacements 
solely in the setting of traumatic indications were not included due to the differing risk profile. 
Disagreements on inclusion or exclusion were discussed by two reviewers (SKK and MCB), with 
involvement of a third reviewer (MRW) when necessary.  
 
2.3. Data extraction and quality assessment 
One author initially extracted data from eligible studies using a standardized predesigned data 
collection form. A second reviewer independently checked these data with that in original articles. 
Any disagreements were discussed, and consensus reached with involvement of a third author. We 
extracted data on study characteristics, sample size, number of VTE outcomes, risk estimates of VTE 
(relative risks (RRs), hazard ratios (HRs), or odds ratios (ORs)) and degree of adjustment for potential 
confounders (univariate or multivariate). To avoid double counting of a cohort, study selection was 
limited to a single set of most comprehensive results when there were multiple publications involving 
the same cohort. The priority for selection was the most up-to-date comprehensive study (longest 
follow-up or analysis covering the largest number of participants). The methodological quality of each 
study was assessed using the nine-star Newcastle-Ottawa Scale (NOS), [10] which uses three pre-
defined domains including: (i) selection of participants; (ii) comparability; and (iii) ascertainment of 
outcomes of interest. The Cochrane Collaboration’s risk of bias tool was used to assess the quality of 
RCTs.[11] 
 
2.4. Data synthesis and analyses 
For the meta-analysis of VTE incidence, the summary measure was incidence (estimated from the 
number of VTE outcomes within follow-up period/total number of participants or procedures as 
reported) with 95% confidence intervals (CIs). Given the nature of the data, the Freeman-Tukey 
variance stabilising double arcsine transformation [12] was used in calculating incidence, because the 
 
 
use of the inverse variance weight in fixed-effects meta-analysis is suboptimal when dealing with 
binary data with low rates. Temporal trends in incidence were evaluated using the median year of data 
collection/surgery reported by studies, as previously reported.[13] Summary measures of associations 
(risk factors for VTE) were presented as RRs with 95% CIs. Following Cornfield’s rare disease 
assumption[14], HRs and ORs were assumed to approximate the same measure of RR. Fully-adjusted 
risk estimates were used when reported, otherwise crude RRs were calculated from studies that 
provided raw counts. Due to the different cut-offs used for BMI by the included studies, we employed 
the following risk comparisons based on the data available: ≥25 vs. <25; ≥30 vs. <30;  ≥35 vs. <35; 
≥40 vs. <40; ≥50 vs. <50 kg/m2 and per unit increase in BMI, to ensure consistency in the pooling 
approach and enhance comparability and interpretation of findings.[9]. Random-effects models using 
the inverse variance weighted method (DerSimonian and Laird) were used to combine RRs to 
minimize the effect of heterogeneity. In the absence of substantial heterogeneity, fixed-effect models 
were employed.  Heterogeneity was assessed and quantified using the Cochrane χ2 statistic and the I2 
statistic.[15] We also estimated 95% prediction intervals to determine the degree of heterogeneity, as 
they provide a region in which about 95% of the true effects of a new study are expected to be 
found.[16, 17] Several pre-defined study-level characteristics which may explain heterogeneity were 
explored using stratified analysis and random effects meta-regression. To assess the potential for 
small study effects or publication bias, we conducted Egger’s regression symmetry test.[18]  All 
statistical analyses were conducted using STATA release 15 (Stata Corp, College Station, Texas, 
USA).   
 
3. Results 
3.1. Study identification and selection 
The review progress is summarised in Figure 1. The literature search and manual screening of 
references identified 79 potentially relevant articles, of which 60 were potentially relevant to the 
review question after screening of titles and abstracts. Following detailed evaluation, 17 articles were 
excluded because (i) they were duplicates of another study included in review (n=8); (ii) population 
was not relevant (n=5); (iii) the outcome was not relevant (n=3); and (iv) study design was not 
 
 
relevant (n=1). The remaining 43 articles corresponding to 24 non-overlapping studies were eligible 
for the review (Figure 1; Appendix D).  
 
3.2. Study characteristics and study quality 
Table 1 provides an overall summary of relevant characteristics of studies included in the review. 
Table 2 provides details of the key characteristics and quality assessment scores of the 43 individual 
articles. Publication years of included articles ranged from 2003-2019. Of the 24 non-overlapping 
studies, only five studies of TER were included in the review. Overall, the studies comprised of 
672,495 total shoulder and elbow replacements or procedures (668,699 TSRs and 3,796 TERs) and 
3,888 VTE cases (3,876 for TSR and 12 for TER). Twenty studies were conducted in North America 
(USA) and four in Europe (Italy and UK). The average baseline age of participants in the eligible 
studies ranged from 51.3 to 72.5 years, with a weighted mean age of 68.9 years; the weighted mean 
age was 69.0 and 57.4 years for TSR and TER respectively. Except for three studies,[5, 19, 20] none 
of the studies provided specific information on type of thromboprophylaxis administered to patients. 
For one study, DVT prophylaxis was initiated after surgery and consisted of enteric coated aspirin 
(325 mg twice a day); pneumatic compression foot pumps; and early ambulation.[5] In the other 
study, low-molecular heparin was used in the majority of cases, with use of unfractionated heparin, 
antiplatelet therapy, or other anticoagulants in a few cases.[19] The third study utilized sequential 
compression devices as DVT prophylaxis.[20] The average follow-up for studies ranged from 30 days 
to 8 years, with a weighted mean follow-up of 0.19 years (approximately 3 months). Methodological 
quality of included studies ranged from 6-9.  Using the Cochrane risk of bias tool for the only RCT 
included, this trial demonstrated a low risk of bias for all areas of study quality except for random 
sequence generation and other bias, which were of unclear risk of bias. 
 
3.3. Incidence of VTE 
Across 19 studies comprising of 668,699 TSRs over a weighted mean follow-up duration of 3 months, 
the pooled random effects incidence (95% CI) of VTE following TSR was 0.85% (0.39-1.46) (Figure 
2). The 95% prediction interval for the summary incidence was 0.00 to 4.80%, suggesting that the true 
 
 
VTE incidence for any single new study will usually fall within this range. There was substantial 
heterogeneity between contributing studies (I2>70%; p < 0.01), which was not explained by any of the 
study-characteristics evaluated (Figure 3). There was no significant evidence of publication bias 
using the Egger test (p=0.326), which was consistent with the absence of selective reporting when 
studies were grouped by size (Figure 3). On exclusion of the study with the highest VTE incidence at 
16.00%,[5] the pooled VTE incidence was 0.66% (0.26-1.22). Furthermore, on single exclusion of the 
study with the second highest VTE incidence at 4.40%,[21] the pooled VTE incidence was 0.64% 
(0.30-1.09). The incidence of DVT and PE following TSR was 0.37% (0.16-0.65) and 0.31% (0.16-
0.49) respectively over a weighted mean follow-up duration ranging from 15 to 26 days (Appendix 
E). The pooled incidence rate of VTE at specific average follow-up periods reported by studies was 
0.10% (0.09-0.11) at <30 days, 0.36% (0.15-0.65) at 30 days, 1.72% (1.54-1.92) at 60 days, 1.17% 
(0.53-2.03) at 90 days, 1.22% (0.99-1.52) at 1 year, 0.96% (0.72-1.25) at 2 years, and 0.44% (0.29-
0.65) at 5 years (Appendix F). Based on the median year of data collection/surgery, the pooled 
incidence rate of VTE was 0.51% (0.39-0.66) in the 1990s, 1.53% (0.57-2.91) in 2000-2009 and 
0.25% (0.05-0.54) in 2010 and beyond (Appendix G1). In meta-regression analysis, there was no 
significant association between VTE incidence rates and median year of data collection/surgery 
(p=0.99) (Appendix G2). 
 
Across 5 studies comprising of 3,796 TERs over a weighted mean follow-up duration of 
approximately 3 months, the incidence of VTE following TER ranged from 0.25% to 9.09%, with a 
pooled incidence (95% CI) of 0.00% (0.00-0.08) (Appendix H). On exclusion of the study with a 
sample size of only 11 joints,[22] the pooled VTE incidence (95% CI) was 0.23% (0.08-0.44). 
 
3.4. Associations of patient-related factors with VTE risk 
Sociodemographic characteristics and BMI  The associations of several sociodemographic 
characteristics and BMI categories with risk of VTE following TSR are reported in Figure 4. Older 
age was associated with an increased risk of VTE when age was evaluated as a categorical or 
continuous variable: RRs (95% CIs) of 1.15 (1.08-1.22) and 1.01 (1.00-1.02) comparing age ≥70 
 
 
years vs <70 years and per one-year increase respectively. Comparing males to females in 4 studies, 
the pooled adjusted RR (95% CI) for VTE was 0.98 (0.86-1.12) (Figure 4; Appendix I). Race was 
not associated with VTE risk in any of the comparisons evaluated. On the role of lifestyle factors, 
alcohol abuse was associated with an increased risk of VTE RR (95% CI) 2.50 (1.82-3.44), with no 
significant association for drug abuse and VTE RR (95% CI) 0.57 (0.08-4.12). Comparing BMIs ≥50 
vs. <50; ≥30 vs. <30; and ≥25 vs. <25 kg/m2, the pooled RRs (95% CIs) were 1.97 (1.63-2.37); 1.28 
(1.09-1.50); and 3.56 (1.21-10.49) respectively.  
 
No studies conducted in patients undergoing primary TER were identified to have formally assessed 
the associations of potential risk factors with risk of VTE. However, one study evaluated the influence 
of obesity on several complications following TER and no significant association could be 
demonstrated between obesity and VTE risk given the zero-event rate.[23] 
 
Medical and surgical history Associations between several medical and surgical history 
characteristics with risk of VTE following TSR are reported in Figure 5. A Deyo-Charlson Index ≥ 1 
was associated with an increase in risk of VTE. In pooled analysis of contributing studies, the 
following comorbidities were each associated with an increased risk of VTE following TSR: chronic 
pulmonary disease, history of VTE, congestive heart failure, anaemia, and coagulopathy. In pooled 
analysis of 3 studies, a history of coronary heart disease was associated with reduced risk of VTE RR 
(95% CI) 0.77 (0.62-0.97). In results of single reports, there was evidence of statistically significant 
associations of VTE with histories of arrhythmia, epilepsy, urinary tract infection, sleep apnoea, and 
fluid & electrolyte imbalance. In evaluation of surgical indications for TSR, neither osteoarthritis, 
avascular necrosis, nor rheumatoid arthritis was associated with VTE risk (Figure 5). 
 
3.5. Associations of surgery- and hospital-related factors with VTE risk 
Comparing anatomic vs. reverse TSR and outpatient TSR vs inpatient TSR, RRs (95% CIs) for VTE 
were 0.59 (0.40-0.87) and 0.43 (0.24-0.76) respectively. Other factors such as implant fixation 
(cemented vs. uncemented), type of anaesthesia (general vs. regional), period or seasonality of 
 
 
surgery, and surgeon experience were not associated with VTE risk following TSR (Appendix J). A 
single study evaluated the association between the altitude of the hospital and the risk of VTE 
following TSR and demonstrated an increased risk of VTE comparing a high altitude (>4000 feet 





Given the variable incidence of VTE following TSR and TER reported in the literature and the lack of 
robust data on the role of potential risk factors that influence VTE risk, we have conducted a 
literature-based meta-analysis that comprehensively summarises the incidence and temporal trends of 
VTE as well as potential associations of patient-, surgery-, and hospital-related factors with the risk of 
VTE following TSR and TER. Based on individual study findings, VTE incidence following TSR 
averaged approximately 0.85% in pooled analysis over an average period of 3 months. The incidence 
of VTE following TSR is not constant in the post-operative period but appears to sharply increase 
from the immediate postoperative period and peaks at 60 days, with a gradual decline afterwards. For 
elbow joints, the 3-month VTE incidence following TER was approximately 0.23%. With regard to 
temporal trends, there appeared to be a decline in the incidence of VTE following TSR from the 
period 2000-2009 to 2010 and beyond, but findings were not robust given the limited data used in the 
analysis. In shoulder replacement patients, several relevant associations were demonstrated. At the 
patient level, older age, alcohol abuse, and high BMI were each associated with an increased risk of 
VTE. Comorbidities associated with an increased risk of VTE were chronic pulmonary disease, 
history of VTE, congestive heart failure, anaemia, coagulopathy, arrhythmia, epilepsy, urinary tract 
infection, sleep apnoea, and fluid & electrolyte imbalance. A history of coronary heart disease was 
associated with a reduced VTE risk. Compared to reverse TSR, anatomic TSR was associated with a 
lower incidence of VTE, which may reflect the observation that reverse TSR is associated with an 
increased risk of complications which include fracture, haematoma, infection, instability, mechanical 
baseplate failure, and scapular notching.[24] Compared to inpatient TSR, outpatient TSR was 
associated with reduced VTE risk, which may reflect a patient selection effect. At the hospital level, a 
high-altitude hospital increased VTE risk compared to a low-altitude hospital.  
 
There have been a number of previous attempts to assess VTE incidence following TSR and TER and 
the role of potential risk factors in VTE development, but these previous reviews have either been 
based on a limited number of reports; focussed on few selected potential risk factors; were conducted 
in the setting of fracture, arthroscopy or hemiarthroplasty; included a mixture of primary and revision 
 
 
joint replacements; or findings were not based on meta-analytic approaches.[4, 25-27] Dattani and 
colleagues, mostly using a narrative approach, reported a VTE incidence of 0.52% and 0.26% for 
shoulder and elbow replacement respectively and identified diabetes, rheumatoid arthritis, and 
ischaemic heart disease to be associated with an increased risk of VTE following shoulder 
surgery.[25] Saleh and colleagues in a narrative synthesis of 14 articles, reported the incidence of 
VTE after shoulder replacement to range from 0.2% to 16.0% and identified factors such as history of 
VTE, thrombophilia, major surgery, advanced age, current malignant disease, immobility, and bed 
confinement to increase the risk of VTE. Though these previous reports provide relevant findings, a 
major limitation in their approach was the use of simple proportions and narrative text to synthesize 
the data; hence, such findings are not robust. By employing relevant statistical approaches which take 
into account the weighted average follow-up period, our review represents the first attempt at 
evaluating and synthesising VTE incidence, temporal trends and the associations of several factors 
with VTE risk in more detail than ever before. 
 
Whether these identified potential risk factors are just risk markers for VTE risk or have causal 
relevance are yet to be ascertained. However, a number of plausible mechanistic pathways may 
explain some of the associations demonstrated. We confirmed the evidence that older age is well 
established to be an independent risk factor for VTE following joint replacement, which has been 
demonstrated in a previous review restricted to hip and knee replacements.[9] It has recently been 
shown in hip and knee replacement patients that females have an increased risk of VTE.[9] In the 
current study, we were unable to show a significant association between gender and VTE risk in TSR. 
Though this finding was based on pooled analysis of only four studies; based on the pooled sample 
size, event rate and confidence intervals, there seemed to be adequate power to demonstrate an 
association if it existed. However, the role of gender in VTE is a contentious topic and inconsistent 
results have always been reported. The relationship between high BMI and increased VTE risk is not 
new and attributed to factors which increase the risk of VTE such as limited mobilisation post-
surgery, increased underlying inflammation, and mechanical restriction to venous return.[28] A 
history of sleep apnoea was associated with an increased risk of VTE, which might reflect the fact that 
 
 
sleep apnoea may be a surrogate measure for obesity, smoking, or cardiopulmonary 
complications;[29, 30] factors which have been consistently shown to increase the risk of VTE.[31] 
Unlike moderate and regular alcohol consumption which has been shown to exert a variety of health 
benefits including decreasing the risk of VTE,[32] alcohol abuse may be associated with an increased 
risk of VTE[33, 34] as demonstrated in our study findings; this has been attributed to an unfavourable 
effect on the coagulation system by increasing levels of factor VII and plasminogen activator 
inhibitor-1.[35] Heavy drinkers are likely to have sleep apnoea and at risk of prolonged 
immobilisation, which are risk factors for VTE. The increased risk of VTE associated with a high 
altitude hospital likely reflects that exposure to high altitude either during air travel, ascent of a 
mountain, or while engaging in sports activities, results in a hypercoagulable state, which predisposes 
to thromboembolic events.[36]  
 
Though only few TSRs and TERs are performed compared to hip and knee replacements,[3] recent 
data suggests that the demand for these upper extremity joint replacements is increasing rapidly and it 
is expected there will be a seven-fold increase in the number of TSRs over the next 15 years.[8] 
Though our limited data suggests that VTE incidence following TSR may be on a temporal decline, 
VTE incidence is expected to rise with the increase in demand for TSRs and TERs and especially 
given that guidelines for thromboprophylaxis in patients undergoing these joint replacements are not 
clearly defined.[4] The social, health and economic costs associated with VTE and its treatment are 
substantial and potentially devastating.[37] Our findings are clinically relevant as we have identified 
several potentially modifiable factors that can be identified and optimised prior to joint surgery. 
Recognition of unmodifiable factors such as older age should aid in careful planning before and after 
surgery such as administering enhanced thromboprophylaxis to these patient groups and ensuring 
early mobilisation. 
 
In addition to several strengths mentioned above, our analyses employed appropriate meta-analytic 
approaches previously not utilised which included taking into account the heterogeneity between 
contributing studies and ensuring that studies with zero rates were not excluded from the pooled 
 
 
analysis; employment of comprehensive data checks to ensure the uniqueness of each study in 
contributing data given that some of the articles were based on the same data; quantification and 
exploration of heterogeneity; subgroup analyses; and exploring for publication bias. We also 
conducted a detailed quality assessment of all studies using a validated tool and none of the studies 
was reported to be of poor quality. The limitations deserve consideration, though these were inherent 
to the included studies and not our approach: (i) the majority of studies included were retrospective 
cohort designs and case series, hence not of high methodological quality; (ii) majority of studies did 
not distinguish between anatomic TSR and reverse TSR; (iii) due to inconsistent or lack of reporting 
of the definition and/or diagnosis of specific VTE endpoints (e.g., symptomatic or asymptomatic DVT 
and PE) and the relatively limited number of studies available for pooling, incidence data could not be 
estimated separately for these endpoints; (iv) furthermore, the wide variability in the incidence 
estimates may suggest that asymptomatic VTE events were included and hence there may be biases in 
the estimates; however, we have no way of knowing this as none of the included studies specifically 
reported asymptomatic VTE events; (v) the majority of studies did not adjust for confounding and 
hence pooling was based on variably adjusted data, therefore the possibility of residual confounding; 
(vi) some of our findings were based on single or few reports, hence require replication in further 
studies; (vii) given that most of the studies were conducted in the USA and UK, the generalizability of 
the findings to other populations is limited; (viii) the majority of studies did not provide specific 
information on type of thromboprophylaxis administered to patients; and (ix) the cutoffs of certain 
risk factors such as alcohol and drug abuse were not provided by the individual studies, hence the 
inability to draw conclusions for clinical application. Given the several limitations, the findings 




Though the incidence of VTE following primary TSR or TER is variable and ranges from 0.04 to 
16%, the average incidence within the first 3 months is less than 1%. The risk of VTE following 
primary TSR may be driven by patient-related factors such as age, BMI, lifestyle factors, and the 
 
 
presence of comorbidities and surgery- and hospital-related factors such as reverse TSR and inpatient 
TSR. High risk groups such as older patients, those with a previous VTE history and those undergoing 
reverse or inpatient TSR may need close monitoring. Modifiable factors such as high BMI, alcohol 
abuse, and comorbidities could be identified and addressed prior to surgery. 
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Figure 1 PRISMA flow diagram 
79 Potentially relevant citations identified
From MEDLINE, Embase, Web of Science, 
Cochrane Library, and reference list of 
relevant studies
19 excluded on the basis of title 
and/ or abstract
17 Articles excluded due to:
8 Duplicate of another study
5 Population not relevant
3 Outcome not relevant
1 Study design not relevant
43 Articles included, based on 24 
unique studies



































Figure 2 Incidence of venous thromboembolism following TSR across eligible studies 
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DVT, deep vein thrombosis; PE, pulmonary embolism; RCT, randomised controlled trial; RTSR, 






Figure 4 Sociodemographic characteristics and body mass index comparisons and risk of venous 
thromboembolism following TSR 
Age
Age ≥70 years vs <70 years
Age ≥60 years vs <60 years
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Figure 5 Medical and surgical history comparisons and risk of venous thromboembolism following 
TSR 
Comorbidity indices
CCI 1 vs 0
CCI 2+ vs 0
ASA grade 3 vs 1-2
ASA grade 4 vs 1-2
Deyo-Charlson Index ≥1 vs 0
Comorbidity
Hypertension vs None
Diabetes mellitus vs None
Chronic pulmonary disease vs None
Malignancy vs None
History of VTE vs None
Coronary heart disease vs None
Congestive heart failure vs None
Anaemia vs None
Coagulopathy vs None
Renal disease vs None










Peptic ulcer disease vs None
Peripheral vascular disease vs None
Urinary tract infection vs None
Valvular disease vs None
Sleep apnoea
Psychosis vs None
Rheumatoid athritis vs None
Fluid & Electrolyte imbalance vs None
Indication for shoulder replacement
Rheumatoid arthritis vs OA
Rheumatoid arthritis vs None
Avascular necrosis vs OA
OA vs no OA
Rheumatologic disease vs None
Previous surgery
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ASA, American Society of Anesthesiologists; CCI, Charlson Comorbidity Index; CHD, coronary 





Table 1. Summary characteristics of included studies (2003-2019) 
 
Characteristics  
Participants N  
Total number of participants or joint replacements 672,495 
Total number of VTE cases 3,888 
Study characteristics  
Location N studies (N participants or joint 
replacements) 
    North America 20 (613,957) 
    Europe 4 (58,538) 
Study design N studies (N participants or joint 
replacements) 
    Retrospective cohorts 20 (666,672) 
    Prospective cohorts 3 (5,715) 
    RCT 1 (108) 
Median (min-max) study quality score 8 (6-9) 
Study level participant characteristics  
Weighted mean (min-max) age, years 68.9 (51.3-72.5) 
Median (IQR) % males 43.7 (36.7-46.7) 
Weighted mean (min-max) follow-up, years 0.19 (0.01-8.00) 
Joint type N studies (N participants or joint 
replacements) 
    Shoulder 19 (668,699) 
    Elbow 5 (3,796) 
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Table 2. Characteristics of studies included in review (2003-2019) 
Author, year of 

















Espag, 2003 1991-2000 UK NR TER Retrospective cohort NR 5.7 years 11 1 NR NA 7 
Lyman, 2006 1985-2003 USA 66.4 TSR Retrospective cohort 39.7 NR 4931 30 NR Multivariable 7 
Duncan, 2007 1981-2001 USA NR TER Retrospective cohort NR 3 days 816 2 PE: CT scan or autopsy NA 8 
Willis, 2009 2003-2004 USA 67.0 TSR Prospective cohort 44.0 12 weeks 100 13 DVT: Doppler ultrasound NA 7 
Jameson, 2011 2005-2008 UK 70.0 TSR Retrospective cohort NR 90 days 4061 8 NR Univariable 7 
Krenek, 2011 1995-2005 USA 56.0 TER Retrospective cohort 36.0 90 days 1625 4 NR NA 9 
Farng, 2011 1995-2005 USA 68.3 TSR Retrospective cohort 46.9 90 days 6009 32 NR NA 6 
Gay, 2012 1997-2006 USA 58.3 TER Retrospective cohort 28.8 90 days 1155 3 NR NA 7 
Singh, 2012 1976-2008 USA 65.0 TSR Prospective cohort 44.0 90 days 4019 47 NR Univariable 9 
Navarro, 2013 2005-2009 USA 72.3 TSR Retrospective cohort 43.7 90 days 2574 14 Doppler ultrasound Univariable 8 
Baghdadi, 2014 1987-2006 USA 62.3 TER Retrospective cohort 24.0 5.8 years 723 1 NR Univariable 8 
Griffin, 2014 200-2008 USA 68.8 TSR Retrospective cohort 38.0 3 days 58790 176 NR NA 8 
Griffin, 2014b 1998-2008 USA 68.8 TSR Retrospective cohort 44.0 3 days 31924 64 NR Univariable 8 
Schairer, 2014 2005-2010 USA 67.5 TSR Retrospective cohort 48.2 90 days 26218 1154 NR NA 8 
Wronka, 2014 NR UK NR TSR Retrospective cohort NR 6 weeks 352 5 
USS Doppler study, VQ scan or CT scan 
of the chest / CTPA NA 8 
Jiang, 2014 2010-2011 USA 69.5 TSR Retrospective cohort 43.0 NR 19497 52 NR Multivariable 9 
Imberti, 2014 2009-2011 Italy 51.3 TSR Prospective cohort 54.4 90 days 121 2 
DVT: Compressive ultrasonography, 
echocolordoppler, CT scan, venography; 
for PE: perfusion lung scan matched with 
chest X-ray, VQ scan, CTPA NA 9 
Saltzman, 2014 2007-2011 USA 72.5 TSR Retrospective cohort 34.0 90 days 137 3 NR NA 8 
Werner, 2015 2005-2012 USA NR TSR Retrospective cohort 38.6 90 days 144239 1928 NR Univariable 6 
Day, 2015 2004-2009 USA 73.0 TSR Retrospective cohort 73-76 90 days 130258 695 NR Multivariable 9 
Young, 2015 2002-2011 USA 69.0 TSR Retrospective cohort 39.7 NR 422372 1058 NR Multivariable 8 
Ponce, 2015 2002-2011 USA 69.0 TSR Retrospective cohort 40.0 NR 422371 844 NR Multivariable 7 
Leroux, 2016 2005-2014 USA 18-85+* TSR Retrospective cohort 51.3 30 days 7197 44 NR Univariable 8 
Villacis, 2016 2011-2013 USA 70.1 TSR Retrospective cohort 45.0 90 days 10844 48 NR Univariable 6 
Churchill, 2016 2002-2011 USA 68.8 TSR Retrospective cohort 40.0 NR 422371 NR NR Multivariable 7 
Fu, 2017 2011-2014 USA NR TSR Retrospective cohort NR 30 days 5918 37 NR Univariable 7 
Basques, 2017 2005-2012 USA NR TSR Retrospective cohort 38.4 90 days 123347 1063 NR Multivariable 8 
Lovy, 2017 2007-2013 USA 63.3 TSR Retrospective cohort 25.0 30 days 189 2 NR NA 7 
Rao, 2017 2005-2012 USA NR TSR Retrospective cohort NR 30 days 1591 8 NR Univariable 8 
Wagner, 2017 1970-2013 USA 68.0 TSR Retrospective cohort 45.0 20.0 years 4567 23 NR Multivariable 8 
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Author, year of 

















Wagner, 2017b 1970-2012 USA 67.0 TSR Prospective cohort 45.0 8.0 years** 5494 24 NR Multivariable 8 
Belmont, 2017 2011-2013 USA 70.1 TSR Retrospective cohort 43.4 30 days 3547 13 NR NA 8 
Ding, 2017 2011-2014 USA 68.4 TSR Retrospective cohort 45.4 90 days 1824 0 NR Univariable 8 
Arshi, 2018 2007-2016 USA 70-74* TSR Retrospective cohort 40.3 60 days 17542 302 NR NA 8 
Chand, 2018 2010-2016 USA 71.7 TSR Retrospective cohort 46.7 90 days 184 3 NR Univariable 6 
Saltzman, 2018 2002-2011 USA 66.0-70.8* TSR Retrospective cohort 40.3 2.8 days 372753 373 NR Multivariable 8 
Damodar, 2018 2005-2014 USA NR TSR Retrospective cohort 43.7 90 days 13964 42 NR Multivariable 9 
Cvetanovich, 2018 2015-2016 USA 66.4 TSR RCT 47.2 90 days 108 1 NR NA NA 
Craig, 2018 1998-2017 UK 72.2 TSR Retrospective cohort 28.0 90 days 58,054 156 NR NA 9 
Wang, 2019 2005-2014 USA NR TSR Retrospective cohort 48.9 90 days 33366 539 NR Univariable 7 
Yin, 2019 2006-2015 USA 63.9 TSR Retrospective cohort 39.0 30 days 2785 9 NR Multivariable 8 
Okoroha, 2019 2007-2015 USA 69.0 TSR Retrospective cohort 42.3 3.8 years 2364 1 NR NA 8 
Scott, 2019 2014 USA 72.3 TSR Retrospective cohort 36.7 90 days 25196 27 NR NA 8 
 
*, age range of participants; **, for participants who did not undergo revision surgery; CT, computed tomography; CTPA, chest tomography pulmonary angiogram; DVT, deep vein thrombosis; NA, not applicable; NR, not 
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Title 1 Identify the report as a systematic review, meta-analysis, or both 1 
Abstract 
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, data sources, study 
eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, 
conclusions and implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known 4-5 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, 
provide registration information including registration number 
2 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years 
considered, language, publication status) used as criteria for eligibility, giving rationale 
6 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched 
6 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated 
Appendix C 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if 




10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators 
6-7 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any 
assumptions and simplifications made 
6-7 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data synthesis 
7-8 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). 7-8 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (such as I2 statistic) for each meta-analysis 
7-8 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, 
selective reporting within studies) 
7-8 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified 
7-8 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram 
8 and Figure 1 
Study characteristics 18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up 
period) and provide the citations 
8-9, Table 1, 
Appendix E 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). 9-10, Appendix E 
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each 
intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
9-10, Figures 2-5  
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency 9-10, Figures 2-5; 
Appendices F, 
9,10,11 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Appendix E 
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) (see 
item 16) 




24 Summarise the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (such as health care providers, users, and policy makers) 
10-11 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete 
retrieval of identified research, reporting bias) 
11-12 




Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role of 





Appendix B. MOOSE checklist  
 
Venous thromboembolism following 672,495 primary total shoulder and elbow 
replacements: meta-analyses of incidence, temporal trends and potential risk factors  
 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
 Problem definition There is uncertainty regarding the exact incidence of venous 
thromboembolism (VTE) following upper extremity joint replacement. 
Whether risk factors for VTE following hip and knee joint replacements 
influence the risk for VTE following upper extremity joint replacement in a 
similar manner is unknown. We conducted a systematic meta-analysis to 
evaluate the incidence of and potential risk factors for VTE following total 
shoulder and elbow replacement. 
 Hypothesis statement Several patient-, surgery-, and hospital-related related factors after upper 
extremity joint replacement. 
 Description of study outcomes Venous thromboembolism 
 Type of exposure  Patient-, surgery-, and hospital-related factors 
 Type of study designs used Longitudinal studies (prospective or retrospective case control, prospective 
cohort, retrospective cohort, case-cohort, nested-case control, or clinical 
trials) 
 Study population Patients followed for VTE outcomes following total shoulder or elbow 
replacement 
Reporting of search strategy should include  
 Qualifications of searchers  
 Search strategy, including time period 
included in the synthesis and keywords 
Time period: from inception to 26 September 2019  
The detailed search strategy can be found in Appendix C 
 Databases and registries searched MEDLINE, EMBASE, Web of Science, and Cochrane databases 
 Search software used, name and version, 
including special features 
OvidSP was used to search EMBASE and MEDLINE 
EndNote used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  The 
citation list for excluded studies are available on request. 
 Method of addressing articles published 
in languages other than English 
Not applicable 
 Method of handling abstracts and 
unpublished studies 
Abstracts with no full text publications were not included. 
 Description of any contact with authors We contacted authors of studies that did not provide adequate data in their 
studies 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled for 
assessing the hypothesis to be tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
 Rationale for the selection and coding of 
data 
Data extracted from each of the studies were relevant to the population 
characteristics, study design, exposure, and outcome. 
 Assessment of confounding We assessed confounding by ranking individual studies on the basis of 
different adjustment levels and performed sub-group analyses to evaluate 
differences in the overall estimates according to levels of adjustment. 
 Assessment of study quality, including 
blinding of quality assessors; 
stratification or regression on possible 
predictors of study results 
Study quality was assessed based on the nine-star Newcastle–Ottawa Scale 
using pre-defined criteria namely: population representativeness, 
comparability (adjustment of confounders), ascertainment of outcome. 
Sensitivity analyses by several quality indicators such as study size, duration 
of follow-up, and adjustment factors. 
 Assessment of heterogeneity Heterogeneity of the studies was quantified with I2 statistic that provides the 
relative amount of variance of the summary effect due to the between-study 
heterogeneity and explored using meta-regression and stratified analyses 
 Description of statistical methods in 
sufficient detail to be replicated 
Description of methods of meta-analyses, sensitivity analyses, meta-
regression and assessment of publication bias are detailed in the methods. We 





 Provision of appropriate tables and 
graphics 
Table 1; Figures 1-5; Appendices E, F, G, H, I, J, K 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 
Figures 2-5; Appendices G, I, J, K 
 Table giving descriptive information for 
each study included 
Appendix E 
 Results of sensitivity testing 
 
Not applicable  
 Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates, I2 
values and results of sensitivity analyses 
Reporting of discussion should include  
 Quantitative assessment of bias Sensitivity analyses indicate heterogeneity in strengths of the association due 
to most common biases in observational studies.  The systematic review is 
limited in scope, as it involves published data. Individual participant data is 
needed. Limitations have been discussed. 
 
 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria in 
methods section. 
 Assessment of quality of included studies Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
 Consideration of alternative explanations 
for observed results 
Discussion 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research We recommend analyses of individual participant data 





Appendix C. Literature search strategy 
Relevant studies, published from inception to 26 September 2019 (date last searched), were identified through 
electronic searches limited to the English language using MEDLINE, Embase, Web of Science, and Cochrane 
databases. Electronic searches were supplemented by scanning reference lists of articles identified for all relevant 
studies (including review articles) and by hand searching of relevant journals.  
 
1     exp Arthroplasty, Replacement, Shoulder/ (736) 
2     exp Arthroplasty, Replacement, Elbow/ (345) 
3     exp Venous Thromboembolism/ (9326) 
4     exp Venous Thrombosis/ (53028) 
5     deep vein thrombosis.mp. (15554) 
6     exp Pulmonary Embolism/ (37391) 
7     exp Thromboembolism/ (53489) 
8     1 or 2 (1079) 
9     3 or 4 or 5 or 6 or 7 (132255) 
10     8 and 9 (15) 










Appendix D. Reference list of 43 included articles 
 
1. Arshi A, Leong NL, Wang C, Buser Z, Wang JC, Vezeridis PS, McAllister DR, Petrigliano 
FA. Relative Complications and Trends of Outpatient Total Shoulder Arthroplasty. 
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Appendix E. Incidence of deep vein thrombosis and pulmonary embolism following primary TSR 
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A, Incidence of TSR VTE by median year of data collection; B, Meta-regression bubble plot of incidence of TSR VTE against 
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CI, confidence interval (bars); RR, relative risk; RTSR; reverse total shoulder replacement; ATSR, anatomic total shoulder 
replacement; VTE, venous thromboembolism 
 
 
 
 
 
